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ABSTRACT	
	
Preclinical	models	propose	that	the	onset	of	psychosis	is	associated	with	hippocampal	hyperactivity,	
thought	 to	be	driven	by	cortical	GABAergic	 interneuron	dysfunction	and	disinhibition	of	pyramidal	
neurons.	 Recent	 neuroimaging	 studies	 suggest	 that	 resting	 hippocampal	 perfusion	 is	 increased	 in	
subjects	at	ultra-high	risk	(UHR)	for	psychosis,	but	how	this	may	be	related	to	GABA	concentrations	is	
unknown.	The	present	study	used	a	multimodal	neuroimaging	approach	to	address	this	issue	in	UHR	
subjects.	 Proton	 magnetic	 resonance	 spectroscopy	 and	 pulsed-continuous	 arterial	 spin	 labeling	
imaging	were	acquired	to	investigate	the	relationship	between	medial	prefrontal	(MPFC)	GABA+	levels	
(including	some	contribution	 from	macromolecules)	and	hippocampal	regional	cerebral	blood	flow	
(rCBF)	in	36	individuals	at	UHR	of	psychosis,	based	on	preclinical	evidence	that	MPFC	dysfunction	is	
involved	in	hippocampal	hyperactivity.	The	subjects	were	then	clinically	monitored	for	2	years:	during	
this	period,	7	developed	a	psychotic	disorder	and	29	did	not.	At	baseline,	MPFC	GABA+	levels	were	
positively	correlated	with	rCBF	in	the	left	hippocampus	(region	of	interest	analysis,	p	=	.044	family-
wise	error	corrected,	FWE).	This	correlation	in	the	left	hippocampus	was	significantly	different	in	UHR	
subjects	who	went	on	to	develop	psychosis	relative	to	those	who	did	not	(p	=	.022	FWE),	suggesting	
the	absence	of	a	correlation	in	the	latter	subgroup.	These	findings	provide	the	first	human	evidence	
that	MPFC	GABA+	concentrations	are	related	to	resting	hippocampal	perfusion	in	the	UHR	state,	and	
offer	some	support	for	a	link	between	GABA	levels	and	hippocampal	function	in	the	development	of	
psychosis.	
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INTRODUCTION	
Post-mortem	and	preclinical	studies	have	provided	consistent	evidence	that	the	pathophysiology	of	
psychotic	disorders	involves	an	alteration	in	GABAergic	neurotransmission	(Benes	and	Berretta,	2001;	
Lewis	 et	 al,	 2005).	 More	 specifically,	 schizophrenia	 has	 been	 linked	 to	 a	 defect	 in	 glutamate	
decarboxylase	 (GAD67)	mRNA	 in	parvalbumin-expressing	 (PV+)	 interneurons	within	a	corticolimbic	
circuit	involving	the	prefrontal	cortex	and	the	hippocampus	(Akbarian	and	Huang,	2006;	Benes,	2010).	
Recent	work	on	a	neurodevelopmental	animal	model	of	psychosis	(Moore	et	al,	2006)	indicates	that	
medial	 prefrontal	 cortex	 (MPFC)	 dysfunction	 leads	 to	 increased	 stress-induced	 functional	 loss	 of	
hippocampal	 PV+	 interneurons	 (Gomes	 and	 Grace,	 2017),	 which	 is	 associated	 with	 hippocampal	
hyperactivity	 through	 disinhibition	 of	 glutamatergic	 pyramidal	 cells	 (Grace,	 2010).	 Increased	
glutamatergic	 output	 from	 the	 ventral	 hippocampus	 is	 hypothesized	 to	 then	 lead	 to	 elevated	
subcortical	 dopamine	 function,	 resulting	 in	 some	 of	 the	 behavioral	 abnormalities	 associated	with	
schizophrenia	 (Grace,	 2016).	 Furthermore,	 independent	 research	 using	 other	 preclinical	 models	
shows	 that	 mutations	 in	 genes	 implicated	 in	 schizophrenia,	 such	 as	 ERBB4	 and	 dysbindin,	 are	
associated	with	disrupted	PV+	interneuron	function	and	dysregulation	of	pyramidal	cell	activity	(Del	
Pino	et	al,	2013;	Wen	et	al,	2010).		
	
Data	from	post-mortem	and	preclinical	studies	thus	suggests	that	cortical	GABAergic	function	
is	 reduced	 in	schizophrenia,	and	that	this	can	be	detected	 in	the	premorbid	stages	of	 the	disorder	
(Modinos	et	al,	2015).	GABA	concentrations	can	be	quantified	in	vivo	using	proton	magnetic	resonance	
spectroscopy	(1H-MRS).	Nonetheless,	studies	comparing	MPFC	GABA	levels	in	patients	and	controls	
have	reported	inconsistent	findings,	including	decreases	(Marsman	et	al,	2014;	Rowland	et	al,	2013;	
Rowland	et	al,	2016),	increases	(Ongur	et	al,	2010),	and	no	significant	differences	(Goto	et	al,	2009;	
Kegeles	et	al,	2012;	Marenco	et	al,	2016;	Tayoshi	et	al,	2010).	Indeed,	a	recent	meta-analysis	did	not	
find	a	significant	difference	in	regional	GABA	levels	between	patients	with	schizophrenia	and	healthy	
volunteers	(Egerton	et	al,	2017b).	There	have	been	relatively	few	1H-MRS	GABA	studies	in	subjects	at	
Modinos	et	al.	
Accepted	manuscript	-	Neuropsychopharmacology	
 4 
ultra-high	risk	(UHR)	of	developing	psychosis,	and	all	of	these	have	examined	GABA	in	the	MPFC.	One	
study	reported	higher	levels	in	subjects	at	UHR	compared	with	controls	(de	la	Fuente-Sandoval	et	al,	
2016);	one	described	lower	GABA	levels	in	UHR	subjects	than	in	controls	(Menschikov	et	al,	2016),	and	
two	studies	including	a	recent	one	from	our	group	found	no	differences	between	UHR	subjects	and	
healthy	 controls	 (Modinos	 et	 al,	 2017;	 Wang	 et	 al,	 2016).	 Despite	 these	 inconsistencies,	 while	
preclinical	models	suggest	that	MPFC	dysfunction	leads	to	hippocampal	overdrive	in	psychosis	(Gomes	
et	al,	2017),	this	has	yet	to	be	explicitly	investigated	in	humans.	
	
Regional	cerebral	blood	flow	(rCBF)	is	directly	correlated	with	the	level	of	local	neural	activity	
(Attwell	et	al,	2010)	and	can	be	quantitatively	measured	using	arterial	spin	labeling	(ASL),	which	uses	
magnetically	labeled	blood	as	endogenous	tracer	(Williams	et	al,	1992).	Studies	using	ASL	suggest	that	
resting	perfusion	is	 increased	in	the	hippocampus	in	 individuals	at	UHR	of	psychosis	(Allen	et	al,	 In	
press;	 Allen	 et	 al,	 2016),	 and	 similar	 findings	 in	 UHR	 have	 been	 reported	 using	 other	 magnetic	
resonance	 imaging	 methods	 involving	 intravenous	 injections	 of	 the	 contrast	 agent	 gadolinium	 to	
measure	basal	cerebral	blood	volume	(Schobel	et	al,	2009).	In	patients	with	schizophrenia	compared	
to	healthy	controls,	hyperperfusion	in	the	hippocampus	has	been	documented	(Friston	et	al,	1992;	
Heckers	and	Konradi,	2015;	 Liddle	 et	al,	 1992),	 as	well	 as	 in	other	brain	 regions	 such	as	 the	basal	
ganglia	and	middle	temporal	lobes	(Pinkham	et	al,	2011),	cerebellum,	brainstem	and	thalamus	(Scheef	
et	al,	2010),	although	the	latter	two	studies	did	not	report	significant	effects	in	hippocampus.	The	aim	
of	 the	 present	 study	 was	 to	 investigate	 whether	 resting	 perfusion	 of	 the	 hippocampus	 in	 UHR	
individuals	may	be	related	to	GABA	levels	in	the	prefrontal	cortex.	We	used	pulsed-continuous	arterial	
spin	labeling	(pCASL)	to	measure	resting	hippocampal	perfusion	and	1H-MRS	to	examine	MPFC	GABA	
levels	in	a	sample	of	individuals	at	UHR	of	developing	psychosis.	For	1H-MRS,	the	MPFC	was	chosen	as	
(i)	this	is	the	most	widely	researched	region	in	1H-MRS	GABA	studies	of	schizophrenia/UHR	subjects	
(Egerton	 et	 al,	 2017a),	 (ii)	 preclinical	models	 indicate	 that	MPFC	deficits	 dysregulate	 hippocampal	
activity	 (Gomes	 et	 al,	 2017),	 and	 (iii)	 measurement	 of	 hippocampal	 GABA	 with	 1H-MRS	 is	 highly	
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technically	 challenging.	 We	 tested	 the	 hypothesis	 that	 MPFC	 GABA	 levels	 would	 be	 negatively	
associated	with	hippocampal	perfusion	in	UHR	subjects.	A	further	prediction	was	that	this	association	
would	be	strongest	in	the	subgroup	of	UHR	subjects	who	subsequently	developed	psychosis.		
	
MATERIALS	AND	METHODS		
Participants	
Ethical	approval	 for	 the	study	was	obtained	 from	the	Research	Ethics	Committee	of	King’s	College	
London	and	South	London	and	Maudsley	(SLaM)	NHS	Trust,	and	all	participants	provided	informed	
consent.	Males	and	females	aged	18-30	were	invited	to	participate	and	the	study	was	completed	by	
36	subjects	at	UHR	of	psychosis.	
	
Participants	were	recruited	from	three	different	clinical	sites,	but	they	all	underwent	pCASL	
and	1H-MRS	scanning	on	a	General	Electric	Signa	HDx	TwinSpeed	3T	scanner	(Milwakee,	Wisconsin)	at	
the	 Centre	 for	 Neuroimaging	 Sciences,	 Institute	 of	 Psychiatry,	 Psychology	 &	 Neuroscience	 (King’s	
College	 London),	 in	 a	 single	 session.	 All	 clinical	 assessments	were	 conducted	 on	 the	 same	 day	 of	
scanning	at	King’s	College	London	by	trained	researchers.	The	different	sites	were:	OASIS	(Outreach	
and	Support	in	South	London)	(Fusar-Poli	et	al,	2013),	part	of	the	SLaM	NHS	Trust	(n	=	22);	CAMEO,	
part	 of	 the	Cambridge	 and	Peterborough	NHS	 Trust	 (n	 =	 11);	 the	West	 London	 Early	 Intervention	
Service	 (n	 =	 2);	 and	 the	 Coventry	 and	Warwick	 NHS	 Trust	 (n	 =	 1).	 Inclusion	 criteria	 involved	 the	
presence	 of	 one	 (or	more)	 of	 the	 following:	 (1)	 attenuated	 psychotic	 symptoms	 (APS),	 (2)	 a	 brief	
psychotic	 episode	of	 less	 than	1	week’s	 duration	 that	 spontaneously	 remits	without	 antipsychotic	
medication	or	hospitalization	(Brief	Limited	Intermittent	Psychotic	episode)	and	(3)	trait	vulnerability	
(schizotypal	personality	disorder	or	a	 first-degree	relative	with	psychosis)	plus	a	marked	decline	 in	
psychosocial	functioning	(Global	Assessment	of	Functioning,	GAF)	(American	Psychiatric	Association,	
1994).	 UHR	 signs	 and	 symptoms	 for	 inclusion	 criteria	 were	 assessed	 with	 the	 Comprehensive	
Assessment	 of	 At-Risk	 Mental	 States	 (CAARMS)	 (Yung	 et	 al,	 2005),	 a	 semi-structured	 interview	
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designed	to	assess	prodromal	psychopathology	in	people	at	UHR	for	psychosis.	All	UHR	subjects	were	
antipsychotic-naïve	and	none	were	on	benzodiazepines	at	the	time	of	scanning.	Eleven	out	of	the	36	
participants	were	currently	taking	antidepressant	medications.	Exclusion	criteria	were	past/present	
diagnosis	 of	 psychotic	 disorders,	 past/present/familiar	 history	 of	 neurological	 illness,	 substance	
abuse/dependence	 as	 defined	 using	 DSM-5	 criteria	 (American	 Psychiatric	 Association,	 1994),	 or	
contraindication	 to	 scanning.	 All	 subjects	 had	 an	 estimated	 premorbid	 IQ	 in	 the	 normal	 range	 as	
assessed	with	the	Wechsler	Adult	Intelligence	Scale-III	(WAIS-III)	(Velthorst	et	al,	2013).		
	
Clinical	Measures	
At	the	time	of	the	scan,	the	following	measures	were	collected:	prodromal	symptomatology	using	the	
CAARMS	 (Yung	 et	 al,	 2005);	 anxiety	 and	 depression	 symptoms	 using	 the	 Hamilton	 Anxiety	 and	
Depression	Scales	(HAM-A	/	HAM-D)	(Hamilton,	1959);	and	social	and	occupational	functioning	using	
the	GAF	(American	Psychiatric	Association,	1994).	Medication	history	and	use	of	alcohol,	tobacco	and	
illicit	 drugs	 was	 assessed	 using	 a	 semi-structured	 interview	 adapted	 from	 the	 Early	 Psychosis	
Prevention	 and	 Intervention	 Centre	 (EPPIC)	 Drug	 and	 Alcohol	 Assessment	 Schedule	
(http://www.eppic.org.au).	 At	 follow-up,	 clinical	 outcomes	 were	 determined	 using	 the	 CAARMS	
Psychosis	Threshold	criteria	(Yung	et	al,	2005)	and	confirmed	with	the	Structured	Clinical	Interview	
for	Diagnosis	(American	Psychiatric	Association,	1994)	as	administered	by	an	experienced	psychiatrist.	
Seven	 of	 the	 UHR	 subjects	 (19%)	 developed	 a	 psychotic	 disorder	 (the	 psychotic	 transition	 group)	
within	 the	 follow-up	 period	 (18	 months).	 These	 disorders	 comprised:	 schizophrenia	 (n	 =	 3),	
schizoaffective	disorder	(n	=	1),	and	bipolar	disorder	(n	=	3).		
	
pCASL	Acquisition	and	Preprocessing	
Parameters	for	data	acquisition,	computation	of	CBF	maps	and	procedures	for	spatial	normalization	
of	these	maps	to	the	reference	space	of	the	Montreal	Neurological	Institute	(MNI)	were	identical	to	
those	described	in	a	separate,	non-overlapping	UHR	sample	(Allen	et	al,	2016).	
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In	brief,	four	pairs	of	control-labeled	pCASL	images	were	acquired	using	a	3D	Fast	Spin	Echo	
(FSE)	stack-of-spiral	multi-shot	readout,	after	a	post-labeling	delay	of	1.5s.	Labeling	of	arterial	blood	
was	achieved	using	a	flow-driven	adiabatic	inversion	approach	(Dai	et	al,	2008),	consisting	of	a	train	
of	1000	Hanning-shaped	RF	pulses	with	a	duration	of	500s	and	an	inter-pulse	gap	of	1ms.	Parameters	
of	the	image	readout	were	as	follows:	TE	=	32.25ms;	TR	=	5500ms;	field	of	view	=	240;	flip	angle	=	
90deg;	60	contiguous	slice	location	of	thickness	3mm	were	obtained	to	achieve	whole	brain	coverage.	
To	 maximize	 sensitivity	 to	 blood	 perfusion,	 background	 suppression	 was	 achieved	 by	 selective	
saturation	of	the	image	slab	at	4.3s	before	acquisition,	selective	inversion	3s	before	acquisition	and	
non-selective	inversions	at	1.5s,	764ms,	334ms	and	84ms	before	imaging.	A	proton-density	calibration	
image	 was	 collected	 with	 the	 same	 sequence.	 This	 image	 was	 used	 to	 quantify	 blood	 flow	 in	
physiological	units	(ml	blood/100gm	tissue/min)	following	the	guidelines	recently	published	for	the	
computation	of	CBF	(Alsop	et	al,	2015).	The	complete	ASL	pulse	sequence	including	the	proton-density	
image	was	performed	in	6min.	For	image	registration	a	high	resolution	T2-weighted	Fast-Relaxation	
Fast	Spin	Echo	(FR-FSE)	image	(TE	=	65.28ms,	TR	=	4380ms,	flip	angle	=	90,	FoV	=	240,	slice	thickness	
=	2mm,	matrix	=	320	x	320mm)	was	employed.		
	
CBF	 maps	 were	 preprocessed	 using	 FMRIB	 Software	 Library	 (FSL)	 software	 applications	
(http://www.fmrib.ox.a.c.uk/fsl)	 and	 Statistical	 Parametric	 Mapping	 (SPM8;	
http://www.fil.ion.ucl.ac.uk/spm/).	A	multi-step	approach	was	performed	including	the	pCASL,	the	T2	
and	 the	 SPGR	 scans:	 (1)	 elimination	 of	 extra-cerebral	 signal	 from	 the	 T2	 scan	 using	 the	 “Brain	
Extraction	 Tool”	 (BET)	 of	 FSL7,	 and	 co-registration	 of	 the	 skull-stripped	 T2	 volume	 and	 its	
corresponding	T2	binary	mask	to	the	pCASL	scan;	(2)	multiplication	of	the	pCASL	scan	(rCBF	map)	with	
the	co-registered	brain	binary	mask	to	remove	extra-cerebral	signal	from	this	scan;	(3)	co-registration	
back	to	the	original	T2	scan	of	the	skull-stripped	CBF	map	following	step	(2);	(4)	normalization	of	the	
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subject’s	T2	and	multiplied	pCASL	(step	2)	with	the	T2	template	from	SPM.	Finally,	spatial	smoothing	
of	the	normalized	individual	CBF	maps	was	carried	out	using	a	6	mm	Gaussian	smoothing	kernel.	
	
1H-MRS	Acquisition	and	Quantification	
GABA+	levels	(including	some	signal	from	unrelated	macromolecules,	i.e.	diverse	proteins	and	lipids)	
were	 obtained	 from	 the	MPFC	 using	MEGA-PRESS,	 which	 incorporates	 a	 standardized	 chemically	
selective	suppression	(CHESS)	water	suppression	routine	(TE	=	68ms,	TR	=	2000ms,	320	averages).	For	
each	acquisition,	unsuppressed	water	reference	spectra	(16	averages)	were	also	acquired.	Shimming	
was	optimized,	with	auto-prescan	performed	twice	before	each	scan.	The	region	of	interest	(ROI)	in	
the	MPFC	was	prescribed	from	the	midline	sagittal	localizer,	and	the	center	of	the	40	×	25	×	30	mm	
ROI,	mostly	covering	the	MPFC	but	also	including	some	contribution	from	anterior	cingulate	cortex,	
was	placed	above	the	middle	section	of	the	corpus	callosum	(Figure	1A).	MEGA-PRESS	scan	duration	
was	 ~13min.	 Structural	 data	 were	 acquired	 by	 means	 of	 a	 three-dimensional	 T1-weighted	
magnetization	prepared	rapid	acquisition	gradient-echo	sequence	(TR	=	6.98	ms,	TE	=	2.85	ms,	voxel	
size	=	1.05	x	1.05	x	1.2mm,	FoV	=	260	mm,	flip	angle	=	11°,	inversion	time	=	400	ms).		
	
Spectra	 were	 analyzed	 using	 LCModel	 version	 6.3-1L	 (http://s-
provencher.com/pages/lcmodel.shtml)	with	the	basis	set	provided	by	its	author	(Provencher,	1993,	
2016).	Water-scaled	 GABA+	 values	 were	 corrected	 for	 the	 voxel	 tissue	 composition	 by	 using	 the	
formula:	Metabolite	 Corrected	 =	Metabolite	 Concentration	 *	 [proportion	white	matter	 +	 (1.283	 *	
proportion	 gray	 matter)	 +	 (1.55	 *	 proportion	 corticospinal	 fluid)]	 /	 (proportion	 white	 matter	 +	
proportion	gray	matter)	 (Gasparovic	et	al,	2006).	Voxel	gray	matter	 (GM),	white	matter	 (WM)	and	
corticospinal	fluid	(CSF)	content	for	each	subject	were	determined	by	extracting	the	location	of	the	
voxel	from	the	spectra	file	headers,	and	using	an	in-house	program	to	calculate	the	percentage	of	GM,	
WM,	and	CSF	content	using	the	segmented	T1-weighted	images.	We	used	(i)	Cramer-Rao	minimum	
variance	bounds	(CRLB)	>	20%	as	reported	by	LCModel,	which	are	estimates	of	fit	of	the	metabolite	
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peaks,	and	(ii)	signal-to-noise	ratio	(SNR)	<	8	to	exclude	poorly-fitted	metabolite	peaks	from	statistical	
analysis	 (Mouchlianitis	et	al,	2016;	Provencher,	2016).	Data	 from	all	36	participants	 in	 the	present	
study	met	these	criteria.	The	GABA	1H-MRS	data	from	the	male	participants	in	this	sample	(n	=	21)	
overlaps	with	the	dataset	recently	reported	as	part	of	a	case-control	study	in	males	(Modinos	et	al,	
2017).	 The	primary	 1H-MRS	measure	was	GABA+	normalized	 to	water	 concentrations	 are	 given	 in	
“institutional	units”.	
	
Statistical	Analysis	
Demographic	data		
Analysis	of	demographic	data	was	performed	with	the	Statistical	Package	for	Social	Sciences	(SPSS)	
version	24	(Chicago,	 IL).	After	confirming	homogeneity	of	variance	with	Levene’s	test,	the	effect	of	
group	 (psychotic	 transition,	non-transition)	on	demographic	and	clinical	variables	was	 tested	using	
independent	 samples	 t-tests	 for	 parametric	 data	 and	 Chi-square	 tests	 for	 non-parametric	 data.	
Significant	effects	are	reported	at	p	<	.05,	two	tailed.	
	
1H-MRS	analysis		
Between-group	 differences	 in	 MPFC	 GABA+	 concentrations	 were	 examined	 with	 an	 independent	
samples	t-test	in	SPSS.	Levene’s	test	was	used	to	check	for	equality	of	variance	across	groups.		
	
pCASL	analysis		
Between-group	 differences	 in	 rCBF	 were	 examined	 with	 an	 independent	 samples	 t-test	 using	
Statistical	Parametric	Mapping	Version	8	(http://www.fil.ion.ucl.ac.uk/spm/software/spm8).	Age	and	
gender	as	covariates	of	no	interests.	Hippocampal	ROIs	were	specified	a	priori	using	the	coordinates	
from	 a	 previous	 rCBF	 study	 in	 a	 separate	 UHR	 sample	 (Allen	 et	 al,	 2016):	MNI	 coordinates	 right	
hippocampus	x,	y,	z	=	20,	-28,	-8	and	left	hippocampus	x,	y,	z	=	-22,	-28,	-8.	These	coordinates	were	
used	for	small	volume	correction	(SVC)	with	a	10mm	sphere.	Results	were	considered	significant	after	
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p	<	.05	with	family-wise	error	correction	(FWE).	For	completeness,	exploratory	whole-brain	analyses	
were	performed	and	are	reported	when	surviving	p	<	 .05	FWE	correction.	This	second	 level	model	
used	the	global	average	CBF	value	over	the	gray	matter	volume	of	each	subject	as	a	covariate,	in	order	
to	account	for	inter-individual	differences	in	global	perfusion	(van	Hell	et	al,	2011).	
	
Integration	of	pCASL	and	1H-MRS	data	
The	relationship	between	hippocampal	rCBF	and	MPFC	GABA+	levels	was	also	investigated	in	SPM8.	
Individual	GABA+	values	were	entered	as	regressors	in	a	voxel-wise	ANOVA,	using	age	and	gender	as	
covariates	of	no	interest,	to	examine	(i)	rCBF-GABA+	associations	across	the	UHR	sample	as	well	as	(ii)	
group	differences	 in	 rCBF-GABA+	associations	 in	UHR	 subjects	who	 later	 transitioned	 to	 psychosis	
(UHR-T)	and	those	who	did	not	(UHR-NT).	Hippocampal	ROIs	were	specified	a	priori	using	the	same	
coordinates	 as	 described	 above	 and	 results	 were	 considered	 significant	 after	 p	 <	 .05	 FWE.	 For	
completeness,	exploratory	whole-brain	analyses	were	performed	and	are	reported	when	surviving	p	
<	.05	FWE	correction.	The	global	average	CBF	value	over	the	gray	matter	volume	of	each	subject	was	
used	as	a	covariate	to	account	for	inter-individual	differences	in	global	perfusion	(van	Hell	et	al,	2011).		
	
Finally,	potential		effects	of		use	of	antidepressant	medication	or	substances	(tobacco,	cannabis	and	
alcohol)	on	our	outcome	measures	(GABA+	levels,	rCBF,	GABA+	and	rCBF	interactions)	were	assessed	
either		in	SPSS	or	by	adding	those	variables	as	covariates		in	the	SPM	designs.	Similarly,	associations	
between	GABA+	levels	and	prodromal	symptom	severity	were	tested	using	Pearson’s	correlation	in	
SPSS.		
	
RESULTS	
Table	1	summarizes	the	participant’s	characteristics.	All	subjects	met	the	APS	criteria	of	the	UHR	state.	
The	UHR-NT	and	UHR-T	subgroups	were	not	significantly	different	in	terms	of	age	(p	=	.734),	gender	
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(p	=	.943),	estimated	IQ	(p	=	.968),	cigarette	(p	=	.182),	cannabis	(p	=	.797),	alcohol	use	(p	=	.399),	or	
antidepressant	use	(p	=	.899).	
	
[Table	1	about	here]	
	
1H-MRS	Spectral	Quality	
Spectra	obtained	were	of	good	quality,	with	LCModel	 reporting	mean	±	SD	signal-to-noise	 ratio	of	
21.94	±	3.46,	line	width	of	6.84	±	2.92	Hz.	UHR	subjects	who	transitioned	to	psychosis	did	not	differ	
from	UHR-NT	 subjects	 in	 any	of	 the	parameters	 relating	 to	GABA+	 spectral	 quality	or	 voxel	 tissue	
content	(Table	2).	
	
1H-MRS	in	UHR	Individuals:	Relationship	to	Clinical	Outcome	
There	was	no	difference	in	GABA+	levels	between	the	UHR-T	and	UHR-NT	subgroups	(t	=	-1.25;	p	=	
.222;	Figure	1B,	Table	2).	Substance	use	and	antidepressant	medication	had	no	significant	effect	on	
GABA+	levels	(tobacco:	r	=	-.094,	p	=	.591;	alcohol:	r	=	-.057,	p	=	.746;	cannabis:	F4,34	=	.484,	p	=	.748;	
antidepressants:	t	=	-.005,	p	=	.996),	and	there	was	no	association	between	GABA+	concentrations	and	
levels	of	CAARMS	Positive	(r	=	-.027,	p	=	.877)	or	Negative	symptoms	(r	=	-.119,	p	=	.495).	
	
[Figure	1	about	here]	
	[Table	2	about	here]	
	
rCBF	in	UHR	Individuals:	Relationship	to	Clinical	Outcome	
Voxel-wise	ROI	analysis	on	hippocampal	rCBF	showed	no	significant	differences	between	UHR-NT	and	
UHR-T	surviving	p	<	.05	FWE	correction.	At	the	whole-brain	level,	UHR-T	subjects	showed	lower	rCBF	
than	UHR-NT	subjects	along	a	cortical	midline	region	encompassing	the	paracentral	 lobule	and	the	
supplementary	motor	area	 (x,	y,	 z	=	2	 -32	60;	T	=	5.51;	Z	=	4.59;	p	=	 .040	FWE)	 (Figure	S1).	These	
Modinos	et	al.	
Accepted	manuscript	-	Neuropsychopharmacology	
 12 
findings	 remained	 unchanged	 after	 adding	 tobacco,	 alcohol	 and	 cannabis	 use	 as	 covariates	 of	 no	
interest	in	the	analysis	(no	suprathreshold	voxels	in	hippocampal	ROI	analysis,	but	lower	rCBF	in	UHR-
T	subjects	in	the	cortical	midline	region	x,	y,	z	=	2	-32	60;	T	=	5.62;	Z	=	4.58;	p	=	.044	FWE).	
	
GABA+	Levels	and	Hippocampal	rCBF	in	UHR	Individuals	
Figure	2	shows	the	relationship	between	GABA+	levels	and	rCBF	in	the	UHR	group,	independent	of	
clinical	outcome.	ROI	analysis	revealed	a	significant	positive	association	between	MPFC	GABA+	levels	
and	rCBF	in	the	left	hippocampus	(x,	y,	z	=	-26,	-20,	-4;	T	=	3.47;	Z	=	3.16;	p	=	.044	FWE).	This	result	
remained	significant	when	adding	tobacco,	alcohol	and	cannabis	use	as	covariates	of	no	interest	(x,	y,	
z	=	-28,	-18,	-6;	T	=	3.30;	Z	=	3.00;	p	=	.040	FWE).	
	
Voxel-wise	whole-brain	 analysis	 revealed	 a	negative	 association	 between	MPFC	GABA+	 levels	 and	
rCBF	in	the	left	ventrolateral	PFC	(x,	y,	z	=	-42,	26,	-12;	T	=	6.15;	Z	=	4.91;	p	=	.011	FWE).	However,	
Cook’s	D	test	identified	one	influential	data	point	in	this	association	(pertaining	to	a	UHR-T	subject).	
Removing	this	subject	from	the	analysis	rendered	the	whole-brain	correlation	between	MPFC	GABA+	
levels	and	rCBF	in	the	ventrolateral	PFC	no	longer	significant	at	p	<	.05	FWE.	No	other	whole-brain	
results	survived	FWE	correction	at	p	<	.05.	
	
[Figure	2	about	here]	
	
	
GABA+	Levels	and	Hippocampal	rCBF	in	UHR	Individuals:	Effect	of	psychotic	transition	
A	significant	group	x	GABA+	x	rCBF	interaction	in	the	left	hippocampus	ROI	(x,	y,	z	=	-18,	-30,	0,	T	=	
3.83,	Z	=	3.43,	p	=	.022	FWE)	indicated	that	the	strength	of	the	association	between	prefrontal	GABA+	
levels	and	hippocampal	rCBF	in	UHR	subjects	who	went	on	to	develop	psychosis	was	different	from	
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that	 in	 those	 who	 did	 not.	 This	 reflected	 a	 strong	 correlation	 in	 the	 subgroup	 who	 developed	
psychosis,	but	the	absence	of	a	correlation	in	the	subgroup	who	did	not	transition	(Figure	3).		
	
	[Figure	3	about	here]	
	
Analysis	of	the	data	on	self-reported	anxiety	measured	with	the	HAM-A	(available	in	n	=	28	subjects:	
21	 UHR-NT	 and	 7	 UHR-T)	 revealed	 a	 trend	 towards	 higher	 anxiety	 levels	 in	 UHR	 subjects	 who	
transitioned	to	psychosis	than	in	those	who	did	not	(t	=	-2.046;	p	=	.051).	However,	Pearson	correlation	
analysis	showed	that	HAM-A	scores	were	not	associated	with	GABA+	levels	(UHR	total:	r	=	-.160,	p	=	
.415;	UHR-NT:	r	=	-.270,	p	=	.237;	UHR-T:	r	=	-.308,	p	=	.502).	Adding	HAM-A	scores	as	covariate	of	no	
interest	in	the	rCBF	group	comparison	rendered	the	whole-brain	finding	of	hypoperfusion	in	a	cortical	
midline	area	no	longer	significant	(p	=	.093	FWE).	HAM-A	scores	were	not	significantly	associated	with	
rCBF	in	UHR-T	versus	UHR-NT	at	p	<	.05	FWE	(either	whole-brain	or	with	hippocampal	ROI	analysis),	
and	the	positive	association	between	GABA+	levels	and	hippocampal	rCBF	remained	significant	after	
using	HAM-A	scores	as	covariate	of	no	interest	in	the	SPM	analysis	(x,	y,	z	=	-26,	-20,	4;	T	=	3.89;	Z	=	
3.33;	p	 =	 .033	FWE). When	antidepressant	medication	was	used	as	 covariate	of	no	 interest	 in	 the	
model	the	result	in	the	hippocampus	remained	significant	for	both	the	across-group	correlation	with	
GABA+	levels	(x,	y,	z	=	-28,	-18,	-6;	T	=	3.26;	Z	=	2.98;	p	=	.041	FWE)	and	the	group	interaction	(x,	y,	z	=	
-18,	-30,	0,	T	=	4.08,	Z	=	3.60,	p	=	.012	FWE).	
	
	
DISCUSSION	
The	 main	 finding	 of	 the	 present	 study	 was	 that	 MPFC	 GABA+	 levels	 were	 related	 to	 resting	
hippocampal	 perfusion	 in	 subjects	 at	 UHR	 of	 developing	 psychosis.	 While	 we	 found	 no	 group	
differences	in	the	standalone	GABA	1H-MRS	or	hippocampal	rCBF	measures,	the	GABA+	correlation	
with	hippocampal	perfusion	appeared	to	be	driven	by	the	UHR	subjects	who	subsequently	developed	
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a	psychotic	disorder:	there	was	a	strong	correlation	in	this	subgroup,	but	no	correlation	in	the	UHR	
subjects	who	did	not	develop	psychosis.	
	
Preclinical	 models	 propose	 that	 cortical	 inhibition	 deficits	 lead	 to	 hippocampal	
hyperexcitability	 in	 psychosis,	 and	 that	 resulting	 increased	 glutamatergic	 outputs	 from	 the	
hippocampus	 to	 the	 striatum	 dysregulate	 subcortical	 dopaminergic	 function	 (Lisman	 et	 al,	 2008).	
Recent	 neuroimaging	 studies	 have	 provided	 data	 partly	 consistent	 with	 such	 models.	 Resting	
hippocampal	hyperperfusion	has	been	described,	compared	with	healthy	controls,	 in	patients	with	
schizophrenia	(Talati	et	al,	2016),	and	in	subjects	at	UHR	for	psychosis	(Allen	et	al,	In	press;	Allen	et	al,	
2016).	Moreover,	within	a	UHR	sample,	the	level	of	hippocampal	hypermetabolism	as	measured	using	
the	contrast	agent	gadolinium	to	map	basal	cerebral	blood	volume	(CBV)	has	been	linked	to	the	risk	
of	later	transition	to	psychosis	(n	=	6)	(Schobel	et	al,	2009).	Independent	work	using	positron	emission	
tomography	(PET)	indicates	that	subcortical	dopamine	function	is	increased	in	psychosis	(Howes	et	al,	
2012)	and	in	UHR	subjects	(Egerton	et	al,	2013;	Howes	et	al,	2011b;	Howes	et	al,	2009;	Mizrahi	et	al,	
2012),	and	that	the	level	of	increase	in	UHR	subjects	is	linked	to	the	later	onset	of	psychosis	(Howes	
et	 al,	 2011a).	 Our	 findings	 expand	 these	 data	 by	 providing	 evidence	 to	 suggest	 that	 distinct	
interactions	between	cortical	GABA+	levels	and	hippocampal	resting	perfusion	may	play	a	role	in	the	
development	of	psychosis.	Although	we	predicted	that	hippocampal	rCBF	would	be	correlated	with	
MPFC	GABA+	levels,	we	expected	that	the	direction	of	the	correlation	would	be	negative	rather	than	
positive.	This	was	based	on	post-mortem	and	preclinical	evidence	that	PV+	interneuron	expression	is	
decreased	in	psychosis	(Benes	et	al,	2001;	Lewis	et	al,	2005;	Lisman	et	al,	2008;	Lodge	et	al,	2009).	
Recent	 evidence	 suggests	 that	 the	 development	 of	 subcortical	 hyperdopaminergia	 in	 rodents	 is	
related	to	a	failure	of	the	MPFC		to	down-regulate	medial	temporal	lobe	activity	(Gomes	et	al,	2017),	
and	that	the	MPFC	can	regulate	hippocampal	and	subcortical	dopamine	neuron	activity	via	the	nucleus	
reuniens	of	the	thalamus	(Zimmerman	and	Grace,	2016).	Human	neuroimaging	studies	suggest	that	
the	polarity	of	the	correlation	between	cortical	activation	and	subcortical	dopamine	function	in	UHR	
Modinos	et	al.	
Accepted	manuscript	-	Neuropsychopharmacology	
 15 
individuals	 may	 differ	 depending	 on	 the	 cortical	 region	 involved:	 a	 positive	 correlation	 has	 been	
reported	 for	 hippocampal	 activation	 (Allen	 et	 al,	 2012),	 but	 a	 negative	 correlation	 for	 prefrontal	
activation	(Fusar-Poli	et	al,	2010).	An	additional	consideration	is	that	in	preclinical	and	post-mortem	
studies	 the	 GABAergic	 abnormality	 appears	 to	 be	 specific	 to	 PV+	 neurons	 (Marin,	 2012),	 which	
account	for	~40%	of	the	cortical	GABAergic	interneuron	population.	In	contrast,	a	limitation	of	1H-MRS	
is	that	it	quantifies	total	tissue	concentrations	as	opposed	to	those	from	a	particular	GABA	cell	type,	
and	 increases	 could	 thus	 reflect	 changes	 in	 other	 classes	 of	 GABA	 interneuron.	 For	 example,	
compensatory	mechanisms	for	a	PV+	deficit	and/or	hippocampal	overdrive	might	involve	increased	
GABA	 levels	 in	PV-	 interneurons	 (Isaacson	and	Scanziani,	2011).	An	alternative	explanation	 for	 the	
observed	positive	correlation	between	MPFC	GABA+	levels	and	hippocampal	resting	perfusion	is	that	
intrinsic	hippocampal	GABAergic	dysfunction	may	result	in	hippocampal	hyperperfusion	in	psychosis	
(Heckers	 et	 al,	 2015)	 and	hence	GABAergic	 increases	 in	MPFC	 (de	 la	 Fuente-Sandoval	 et	 al,	 2016;	
Kegeles	et	al,	2012)	may	be	compensatory	in	nature.	Noteworthy,	the	measurement	of	hippocampal	
GABA	 function	 using	 1H-MRS	 is	 technically	 challenging	 and	 only	 one	 such	 study	 to	 date	 has	 been	
published,	 reporting	 no	 significant	 differences	 between	 patients	 with	 schizophrenia	 and	 healthy	
controls	(Stan	et	al,	2014).	Future	work	measuring	GABAergic	function	in	homologous	regions	across	
species	with	similar	imaging	methods	may	comprehensively	delineate	the	molecular	pathway	linking	
GABAergic	dysfunction	to	the	expression	of	schizophrenia-like	characteristics.	
	
Exploratory	analysis	of	the	associations	between	levels	of	GABA+	in	the	MPFC	and	whole-brain	
rCBF	revealed	a	significant	negative	association	with	the	left	ventrolateral	PFC,	which	was	strongest	
in	the	subgroup	of	UHR	subjects	who	later	transitioned	to	psychosis.	Nevertheless,	this	effect	was	no	
longer	significant	once	anxiety	 levels	(HAM-A)	were	included	in	the	analysis,	suggesting	a	potential	
relationship	between	this	whole-brain	finding	and	anxiety	levels	in	the	UHR	state.	The	ventrolateral	
PFC	 plays	 a	 major	 role	 in	 cognitive	 control	 processes,	 particularly	 in	 the	 cognitive	 regulation	 of	
emotional	states	(Goldin	et	al,	2008;	Ochsner	and	Gross,	2005).	Difficulties	with	emotion	regulation	
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are	proposed	to	be	a	core	feature	of	anxiety	disorders	 (Campbell-Sills	and	Barlow,	2007),	 in	which	
reduced	 functional	 activation	 of	 ventrolateral	 PFC	 regions	 is	 a	 robust	 finding,	 along	 with	
hyperresponsivity	of	 limbic,	emotion-generation	regions	(Etkin	and	Wager,	2007).	Although	we	did	
not	have	a	specific	hypothesis	about	this	brain	area,	the	direction	of	the	association	with	GABA+	levels	
(negative)	 aligns	 with	 what	 would	 be	 hypothesized	 from	 preclinical	 and	 post-mortem	 findings.	
Although	 speculative,	 a	 potential	 explanation	 may	 be	 that	 altered	 GABA-perfusion	 interactions	
between	cognitive	control	regions	might	lead	to	inefficient	down-regulation	of	anxiety	experiences	in	
UHR	subjects,	particularly	in	those	who	later	develop	psychosis	(who	did	show	a	trend	towards	higher	
self-reported	anxiety	than	subjects	who	did	not	develop	psychosis,	p	=	 .051).	These	findings	are	of	
interest	and	merit	further	research	in	larger	samples.	
	
	 In	 terms	of	 limitations,	 the	present	 study	was	part	of	 a	 larger	multimodal	 imaging	project	
investigating	 the	 neurobiology	 of	 psychosis	 onset	 in	 UHR	 individuals,	 following	 an	 asymmetric	
prospective	design.	Both	rCBF	and	1H-MRS	data	could	not	be	collected	for	the	relatively	small	number	
of	healthy	controls	included	in	the	larger	project,	which	precluded	the	inclusion	of	a	comparison	group	
in	 this	 circuit-based	 UHR	 study.	 Furthermore,	 the	 size	 of	 the	 UHR	 sample	 limited	 the	 number	 of	
subjects	transitioning	to	psychosis	by	the	follow-up	point;	the	longitudinal	results	between	UHR-T	and	
UHR-NT	must	thus	be	interpreted	with	caution.	Future	longitudinal	studies	in	larger	UHR	samples	are	
warranted	 to	 clarify	 the	 prediction	 value	 of	 GABA-perfusion	 interactions	 for	 psychosis	 onset,	
confirm/refute	the	nature	of	our	positive	findings,	and	elucidate	whether	these	are	transdiagnostic	or	
rather	specific	to	different	types	of	psychotic	disorders.	There	was	a	trend	towards	higher	levels	of	
anxiety	 in	 the	 subgroup	 that	 transitioned	 to	 psychosis,	 but	 no	 significant	 association	 was	 found	
between	anxiety	scores	and	levels	of	GABA+,	and	the	GABA-hippocampal	rCBF	associations	and	group	
interactions	remained	significant	when	HAM-A	scores	were	included	as	covariate	of	no	interest	in	the	
analysis.	 Finally,	 regarding	MEGA-PRESS	 acquisition,	 the	 size	 of	 our	MPFC	 voxel	meant	 that	 some	
portion	of	anterior	cingulate	cortex	was	also	included.	In	addition,	a	limitation	intrinsic	to	all	MEGA-
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PRESS	studies	is	that	the	GABA	signal	contains	some	contribution	from	macromolecules,	i.e.	diverse	
proteins	and	 lipids.	However,	at	present,	 there	 is	no	evidence	to	suggest	 that	the	macromolecular	
contribution	would	differ	between	the	UHT-T	and	UHR-NT	subgroups.	
	
In	summary,	our	study	indicates	that,	in	individuals	at	ultra-high	risk	of	developing	psychosis,	
the	level	of	resting	hippocampal	perfusion	was	related	to	prefrontal	GABA+	levels.	Furthermore,	the	
data	suggests	that	this	association	was	present	the	UHR	subjects	who	went	on	to	develop	a	psychotic	
disorder	and	absent	in	those	who	did	not,	although	the	study	did	not	identify	significant	differences	
between	UHR-NT	and	UHR-T	subjects	in	either	hippocampal	rCBF	or	GABA	1H-MRS	alone.	In	light	of	
recent	 evidence	 demonstrating	 that	 peripubertal	 pharmacological	 intervention	 on	 the	 GABAergic	
system	in	a	rodent	model	of	psychosis	can	block	the	development	of	striatal	hyperdopaminergia	in	
adulthood	(Du	and	Grace,	2013,	2016;	Gill	et	al,	2011),	further	research	is	warranted	to	investigate	
whether	clinical	interventions	in	the	high-risk	phase	targeting	this	pathway	may	have	the	potential	to	
reduce	the	risk	of	developing	psychosis.	
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Table	1.	Participant	demographic	and	clinical	characteristics	at	presentation.	
	
	 Total	UHR	
(n=36)	
Non-transition	
(n=29)	
Transition	
(n=7)	
UHR-NT	vs	UHR-T	
	 Mean	(SD)	 Mean	(SD)	 Mean	(SD)	 Statistic	 p	
Age	(years)	 21.8	(2.9)	 21.7	(2.9)	 22.1	(3.0)	 t	=	.342	 .734	
Gender	(male	/	female)	 21	/	15	 17	/	12	 4	/	3	  c2	=	.005	 .943	
Estimated	IQ	 107.6	(11.6)	 107.8	(12.3)	 106.2	(7.3)	 t	=	-.276	 .784	
CAARMS	Positive	 11.9	(4.2)	 11.8	(4.1)	 12.6	(3.3)	 t	=.443	 .661	
CAARMS	Negative	 6.9	(4.42)	 6.8	(4.2)	 7.1	(5.7)	 t	=.173	 .864	
GAF	 58.3	(11.6)	 58.5	(11.3)	 57.9	(13.5)	 t	=	-.121	 .905	
HAM-A	 21.0	(11.7)	 18.6	(11.0)	 28.4	(11.4)	 t	=	2.046	 .051	
HAM-D	 19.2	(11.3)	 17.4	(11.9)	 24.6	(7.6)	 t	=	1.485	 .149	
Tobacco	(cigarettes/day)	 5.4	(8.2)	 6.4	(8.8)	 1.7	(3.3)	 t	=	-1.362	 .182	
Alcohol	(units/day)	 2.3	(4.6)	 2.7	(5.1)	 1.0	(0.6)	 t	=	-.854	 .399	
Cannabis	(median	[range])	 0	(0	–	4)	 0	(0	–	4)	 1	(0	–	4)	  c2	=	1.667	 .797	
Antipsychotic	medication	 0	 -	 -	 -	 -	
Benzodiazepines	 0	 -	 -	 -	 -	
Antidepressant	 medication	
(y/n)	
11/25	 9/20	 2/5	  c2	=	.016	 .899	
	
CAARMS:	 Comprehensive	 Assessment	 of	 At	 Risk	 Mental	 States;	 Cannabis/alcohol	 use:	 0=never,	
1=experimental	use	(has	tried	occasionally),	2=occasional	use	(has	used	small	quantities	from	time	to	
time),	3=moderate	use	(has	used	in	small	quantities	regularly	/	large	amounts	occasionally),	4=severe	
use	(has	frequently	used	large	quantities,	often	to	intoxication/debilitation);	GAF:	Global	Assessment	
of	Functioning;	HAM-A/D:	Hamilton	Anxiety	and	Depression	Scales.	
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Table	2.	1H-MRS	quality	parameters	and	metabolite	levels.	
	 Total	UHR	
(n=36)	
Non-
transition	
(n=29)	
Transition	
(n=7)	
UHR-NT	vs	UHR-T	
	 Mean	(SD)	 Mean	(SD)	 Mean	(SD)	 Statistic	 p	
SNR	 21.9	(3.5)	 21.8	(3.2)	 22.7	(4.7)	 .650	 .520	
Line	width	 6.8	(2.9)	 7.0	(3.1)	 6.2	(1.7)	 -.692	 .494	
Voxel	CSF	 0.1	(0.1)	 0.1	(0.0)	 0.2	(0.1)	 .539	 .593	
Voxel	GM	 0.5	(0.4)	 0.5	(0.0)	 0.5	(0.0)	 -.497	 .622	
Voxel	WM	 0.3	(0.1)	 0.3	(0.0)	 0.3	(0.1)	 -.059	 .953	
GABA+	 3.9	(0.7)	 3.8	(0.6)	 4.2	(0.9)	 1.245	 .222	
GABA+	%	CRLB	 5.8	(1.9)	 5.9	(1.5)	 5.3	(1.4)	 -.948	 .350	
CRLB:	Cramer-Rao	Lower	Bounds,	CSF:	cerebrospinal	fluid,	GM:	gray	matter,	SNR:	signal	to	noise	ratio,	
WM:	white	matter.	 	
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FIGURE	LEGENDS	
	
	
	
	
	
Figure	1.	(A)	Location	of	MEGA-PRESS	voxel	on	the	medial	prefrontal	cortex	and	representative	MRS	
spectrum.	(B)	Mean	GABA+	concentrations	by	group.	Light	circles	represent	ultra-high	risk	subjects	
who	later	transitioned	to	psychosis	and	dark	circles	those	who	did	not.		
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Figure	2.	Baseline	positive	association	in	UHR	subjects	between	levels	of	GABA+	in	the	MPFC	and	rCBF	
in	the	left	hippocampus.	rCBF	values	are	expressed	as	ratio	over	global	rCBF.	Significant	effects	at	p	<	
0.05	FWE,	shown	at	p	<	.005	uncorrected	for	display	purposes.	
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Figure	 3.	 Plots	 depicting	 the	 group	 by	 GABA+	 by	 rCBF	 interaction	 in	 left	 hippocampus	 from	 ROI	
analysis.	 Regression	 slopes	 were	 significantly	 different	 between	 UHR	 subjects	 with	 psychotic	
transition	(UHR-T)	and	UHR	subjects	without	transition	(UHR-NT).	rCBF	values	are	expressed	as	ratio	
over	global	rCBF.	Significant	effects	at	p	<	0.05	FWE.	
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SUPPLEMENTARY	RESULTS	
	
rCBF	in	UHR	Individuals:	Relationship	to	Clinical	Outcome	
	
Figure	S1.	Section	overlay	and	plot	depicting	rCBF	differences	between	the	UHR-NT	and	UHR-T	groups	
at	the	whole-brain	level.	rCBF	values	are	expressed	as	ratio	over	global	rCBF.	Significant	effects	at	p	<	
0.05	FWE,	shown	at	p	<	.005	uncorrected	for	display	purposes.	
	
	
	
